ZELAPAR Drug Patent Profile
✉ Email this page to a colleague
When do Zelapar patents expire, and what generic alternatives are available?
Zelapar is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in ZELAPAR is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zelapar
A generic version of ZELAPAR was approved as selegiline hydrochloride by I3 PHARMS on April 1st, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZELAPAR?
- What are the global sales for ZELAPAR?
- What is Average Wholesale Price for ZELAPAR?
Summary for ZELAPAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 97 |
Clinical Trials: | 3 |
Patent Applications: | 4,401 |
Drug Prices: | Drug price information for ZELAPAR |
What excipients (inactive ingredients) are in ZELAPAR? | ZELAPAR excipients list |
DailyMed Link: | ZELAPAR at DailyMed |
Recent Clinical Trials for ZELAPAR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of South Florida | Phase 4 |
Bausch Health Americas, Inc. | Phase 4 |
Parkinson's Disease and Movement Disorder Center of Boca Raton | Phase 4 |
Pharmacology for ZELAPAR
Drug Class | Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor |
Mechanism of Action | Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors |
US Patents and Regulatory Information for ZELAPAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZELAPAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | ⤷ Sign Up | ⤷ Sign Up |
Bausch | ZELAPAR | selegiline hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021479-001 | Jun 14, 2006 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZELAPAR
See the table below for patents covering ZELAPAR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1085081 | ⤷ Sign Up | |
Cyprus | 2175 | Pharmaceutical and other dosage forms | ⤷ Sign Up |
Greece | 3029555 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |